| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H18N2O3 |
| Molecular Weight | 226.2722 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
InChI
InChIKey=VIROVYVQCGLCII-UHFFFAOYSA-N
InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
| Molecular Formula | C11H18N2O3 |
| Molecular Weight | 226.2722 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AMOBARBITAL is a barbiturate derivative with hypnotic and sedative properties. In an in vitro study in rat thalamic slices amobarbital worked by activating GABAA receptors, which decreased input resistance, depressed burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increased both the amplitude and decay time of inhibitory postsynaptic currents. Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Sedative: 30 to 50 mg given 2 or 3 times daily.
Hypnotic: 65 to 200 mg at bedtime.
Route of Administration:
Oral
To 100mkl of the tissue homogenate were added 50 mkl of [3SS]TBPS (at the appropriate concentration, and made in 1 M NaBr), 50 mkl of 50 mM Tris Citrate buffer (to define total binding) or AMOBARBITAL at 100mkM or 50mkl of 40mkM picrotoxinin (to define nonspecific binding). The mixture was incubated 90 min at 21°C and then filtered over glass-fiber filters (Schleicher and Schuell No. 32). Filters were washed three times with 5 ml 0.9% (w:v) NaC1 equilibrated to 21°C and then counted by liquid scintillation spectrometry.
